Kymera Therapeutics(NASDAQ) KYMR

Kymera Therapeutics makes oral pills that remove disease-causing proteins. These medicines help patients with inflammatory conditions and cancer. The company creates daily pills to replace complex medical injections.

Pills for Protein Cleanup

• STAT6 Program: Oral medicines targeting inflammatory diseases like atopic dermatitis and asthma; includes the candidate KT-621 currently in Phase 2b clinical trials.
• IRF5 Program: Small molecule degraders designed to treat immune-inflammatory disorders; lead candidate KT-579 is being evaluated in a Phase 1 clinical trial.
• IRAK4 Program: Immunology therapy developed in collaboration with Sanofi for conditions like hidradenitis suppurativa; candidate KT-485/SAR447971 entered Phase 1 testing in 2026.
• CDK2 Program: Cancer-fighting molecular glue degraders being developed with Gilead Sciences; lead candidate KT-200 is currently in early-stage studies.

Key Strategic Growth Steps

• Entered an exclusive option and license agreement with Gilead Sciences in June 2025 to develop CDK2 degraders.
• Achieved a $20 million clinical milestone from Sanofi in June 2026 following the start of human clinical trials.
• Received a $45.0 million option exercise payment from Gilead Sciences in April 2026 for the oral candidate KT-200.
• Signed a sales agreement with Cowen in Feb. 2026 to allow for potential common stock offerings of up to $500.0 million.

Innovative Protein Disposal

Kymera uses targeted protein degradation, which engages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. This platform allows the company to address biological targets that have been difficult to treat with standard drug technologies.

Recent Financial Facts

• Collaboration revenue was $65.0 million for the three-month period ended June 30, 2026.
• Market cap hit $11.3 billion in the second quarter of 2026, up 220.7% year over year.
• Research and development expenses were $217.6 million for the six-month period ended June 30, 2026.
• Total cash, cash equivalents, and marketable securities were $1,505 million as of June 30, 2026.
• The price-to-earnings ratio was -46.2 as of the second quarter of 2026.

Bottom Line

Kymera has evolved into a clinical-stage leader in targeted protein degradation with several drug candidates currently in human trials. Its major pharmaceutical partnerships and significant cash reserves support a transition toward becoming a fully integrated biopharmaceutical company.